# Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-old

> **NCT00510003** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 117 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Pimecrolimus

## Key facts

- **NCT ID:** NCT00510003
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2006-01
- **Final completion:** —
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00510003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00510003, "Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-old". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00510003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*